LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

LLY

737.06

+2.22%↑

JNJ

149.44

+1.99%↑

UNH

270.56

-12.95%↓

ABBV

181.13

+2.05%↑

NVO

65.88

+2.58%↑

Начало・Списък с акции・Essa Pharma Inc

Essa Pharma Inc

Отворен

1.68 1.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.65

Максимум

1.68

Ключови измерители
By Trading Economics
Приходи	2.2M -6.4M
EPS	-0.195
Служители	35
EBITDA	-2.2M -8.5M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.3M 75M
Предишно отваряне	-0.14
Предишно затваряне	1.68

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

1.7 / 1.72 Подкрепа & съпротива

Essa Pharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.05.2025 г., 23:40 ч. UTC

Горещи акции

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14.05.2025 г., 23:33 ч. UTC

Значими двигатели на пазара

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14.05.2025 г., 23:25 ч. UTC

Значими двигатели на пазара

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14.05.2025 г., 23:25 ч. UTC

Печалби

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14.05.2025 г., 22:58 ч. UTC

Печалби

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14.05.2025 г., 21:35 ч. UTC

Печалби

Cisco Systems Names Patterson as CFO, Patel as President

14.05.2025 г., 23:59 ч. UTC

Пазарно говорене

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14.05.2025 г., 23:49 ч. UTC

Пазарно говорене

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14.05.2025 г., 23:48 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14.05.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Gains on Possible Technical Recovery -- Market Talk

14.05.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14.05.2025 г., 23:10 ч. UTC

Печалби

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14.05.2025 г., 23:07 ч. UTC

Печалби

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14.05.2025 г., 23:00 ч. UTC

Топ новини

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14.05.2025 г., 22:43 ч. UTC

Печалби

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14.05.2025 г., 22:34 ч. UTC

Печалби

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14.05.2025 г., 22:33 ч. UTC

Печалби

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14.05.2025 г., 22:30 ч. UTC

Печалби

Xero Did Not Declare a Dividend>XRO.AU

14.05.2025 г., 22:30 ч. UTC

Печалби

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14.05.2025 г., 22:30 ч. UTC

Печалби

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14.05.2025 г., 22:30 ч. UTC

Печалби

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14.05.2025 г., 22:28 ч. UTC

Печалби

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14.05.2025 г., 22:28 ч. UTC

Печалби

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14.05.2025 г., 22:27 ч. UTC

Печалби

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14.05.2025 г., 22:27 ч. UTC

Печалби

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14.05.2025 г., 22:23 ч. UTC

Топ новини

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14.05.2025 г., 22:15 ч. UTC

Печалби

Correction to Cisco Earnings Article -- WSJ

14.05.2025 г., 21:48 ч. UTC

Печалби

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14.05.2025 г., 21:37 ч. UTC

Печалби

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Essa Pharma Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Essa Pharma Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.7 / 1.72Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.